ZS Pharma (ZSPH) Posts Q4 Loss of 98c/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/11/2026
- Wall Street ends down as expectations of Hormuz deal fade
- JPMorgan lifts S&P 500 target to 8,000 on strong earnings
- Nvidia and Wall Street giants plan $500B AI funding deal, FT reports
- Jefferies cuts Apple rating as higher-priced iPhone roadmap looks difficult
- Oil climbs 5% as Iran, US both demand compensation and Hormuz hopes fade
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
- After-Hours Movers: SPCX, AMD, ANET, PINS, APPS, UPST, ZETA, BKNG, LCID, CPNG, MTCH
- After-Hours Stock Movers: PLTR, SNAP, ON, ICHR, WGS, WHR
ZS Pharma Reports Fourth Quarter and Year-End 2014 Financial Results and Provides ZS-9 Program Update
March 13, 2015 7:00 AM EDTREDWOOD CITY, Calif., March 13, 2015 (GLOBE NEWSWIRE) -- ZS Pharma, Inc. (Nasdaq: ZSPH), a biopharmaceutical company focused on the development and commercialization of highly selective, non-absorbed drugs to treat renal, cardiovascular, liver and metabolic disorders, today provided a program update on ZS-9 (sodium zirconium cyclosilicate), the Company's investigational treatment for hyperkalemia, and reported its financial results for the fourth quarter and year ended December 31, 2014.
"We made significant progress with ZS-9 last year including the publication of our Phase 3 trials in JAMA and NEJM highlighting the interest from the medical community in hyperkalemia... More
ZS Pharma Reports Fourth Quarter and Year-End 2014 Financial Results and Provides ZS-9 Program Update
March 13, 2015 7:00 AM EDTREDWOOD CITY, Calif., March 13, 2015 (GLOBE NEWSWIRE) -- ZS Pharma, Inc. (Nasdaq: ZSPH), a biopharmaceutical company focused on the development and commercialization of highly selective, non-absorbed drugs to treat renal, cardiovascular, liver and metabolic disorders, today provided a program update on ZS-9 (sodium zirconium cyclosilicate), the Company's investigational treatment for hyperkalemia, and reported its financial results for the fourth quarter and year ended December 31, 2014.
"We made significant progress with ZS-9 last year including the publication of our Phase 3 trials in JAMA and NEJM highlighting the interest from the medical community in hyperkalemia... More
